scholarly journals Prevalence of adult atopic dermatitis in the general population, with a focus on moderate to severe disease: results from the Lifelines Cohort Study

2021 ◽  
Author(s):  
Junfen Zhang ◽  
Laura Loman ◽  
Angelique N. Voorberg ◽  
Marie L.A. Schuttelaar
Keyword(s):  
Atopic Dermatitis ◽  
Cohort Study ◽  
General Population ◽  
Severe Disease

scholarly journals Four phenotypes of atopic dermatitis in Japanese children: A general population birth cohort study

2019 ◽  
Vol 68 (4) ◽  
pp. 521-523 ◽  
Author(s):  
Kiwako Yamamoto-Hanada ◽  
Limin Yang ◽  
Mayako Saito-Abe ◽  
Miori Sato ◽  
Yusuke Inuzuka ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cohort Study ◽  
General Population ◽  
Birth Cohort ◽  
Birth Cohort Study ◽  
Japanese Children

scholarly journals Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tracey G. Simon ◽  
Hannes Hagström ◽  
Rajani Sharma ◽  
Jonas Söderling ◽  
Bjorn Roelstraete ◽  
...  
Keyword(s):  
Cohort Study ◽  
Liver Disease ◽  
General Population ◽  
Chronic Liver Disease ◽  
Cox Regression ◽  
Severe Disease ◽  
Chronic Liver ◽  
Nonalcoholic Fatty Liver ◽  
Increased Risk ◽  
Population Controls

Abstract Background and aims Some, but not all, prior studies have suggested that patients with chronic liver disease are at increased risk of contracting COVID-19 and developing more severe disease. However, nationwide data are lacking from well-phenotyped cohorts with liver histology and comparisons to matched general population controls. Methods We conducted a nationwide cohort study of all Swedish adults with chronic liver disease (CLD) confirmed by liver biopsy between 1966 and 2017 (n = 42,320), who were alive on February 1, 2020. CLD cases were matched to ≤ 5 population comparators by age, sex, calendar year and county (n = 182,147). Using Cox regression, we estimated multivariable-adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for COVID-19 hospitalization and severe COVID-19 (intensive care admission or death due to COVID-19). Results Between February 1 and July 31, 2020, 161 (0.38%) CLD patients and 435 (0.24%) general population controls were hospitalized with COVID-19 (aHR = 1.36, 95% CI = 1.11–1.66), while 65 (0.15%) CLD patients and 191 (0.10%) controls developed severe COVID-19 (aHR = 1.08, 95% CI = 0.79–1.48). Results were similar in patients with CLD due to alcohol use, nonalcoholic fatty liver disease, viral hepatitis, autoimmune hepatitis, and other etiologies. Among patients with cirrhosis (n = 2549), the aHRs for COVID-19 hospitalization and for severe COVID-19 were 1.08 (95% CI 0.48–2.40) and 1.23 (95% CI = 0.37–4.04), respectively, compared to controls. Moreover, among all patients diagnosed with COVID-19, the presence of underlying CLD was not associated with increased mortality (aHR = 0.85, 95% CI = 0.61–1.19). Conclusions In this nationwide cohort, patients with CLD had a higher risk of hospitalization for COVID-19 compared to the general population, but they did not have an increased risk of developing severe COVID-19.

Sign in / Sign up

Export Citation Format

Share Document